Amoy Diagnostics Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Amoy Diagnostics Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amoy Diagnostics Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amoy Diagnostics Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amoy Diagnostics Co Ltd (AmoyDx) is a pharmaceutical company that develops molecular diagnostics for oncology precision medicine. The company's products include immunohistochemistry (IHC), polymerase chain reaction (PCR) products, next-generation sequencing (NGS) products, fish products, and nucleic acid extraction products. It markets its products under the brand names ADx-ARMS, Super-ARMS, ADx-HANDLE, and Handle Technology. Its products and services are used by healthcare providers to improve patient care, particularly in the field of oncology. The company markets its products through a network of distributors in Taiwan, Hong Kong, Bangkok, the Philippines, and Malaysia, among others. AmoyDx is headquartered in Xiamen, Fujian, China.
Headquarters
China
Address
No.39, Dingshan Road, Haicang District, Xiamen, Fujian, 361027
Website
www.amoydx.com
Telephone
86 592 6806830
No of Employees
1,144
Industry
Medical Equipment
Ticker Symbol & Exchange
300685 (SHE)
Revenue (2024)
$154.3M
6.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-2.5%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
-8.3%
(2024 vs 2023)
* As of and is in US$
Amoy Diagnostics Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Immunohistochemistry (IHC) Products | Super-ARMS |
| Polymerase Chain Reaction (PCR) Products | ADx-ARMS |
| Next-Generation Sequencing (NGS) Products | ADx-HANDLE |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company's AmoyDx received approval from the National Medical Products Administration in China for the companion diagnostic for MET exon 14 skipping mutations for Tabrecta (Capmatinib Hydrochloride Tablets). |
| 2025 | Regulatory Approval | In September, the company and Precision Medicine Asia Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare for the AmoyDx Pan Lung Cancer PCR Panel as a Companion Diagnostic for Taletrectinib adipate (IBTROZI). |
| 2024 | Contracts/Agreements | In May, the company partnered with Boehringer Ingelheim to develop a Companion Diagnostic kit to identify non-small cell lung cancer patients. |
Competitor Comparison
| Key Parameters | Amoy Diagnostics Co Ltd | Guangzhou Wondfo Biotech Co Ltd | Shanghai Kehua Bio-engineering Co Ltd | Beijing Strong Biotechnologies Inc | Dirui Industrial Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Xiamen | Guangzhou | Shanghai | Beijing | Changchun |
| State/Province | Fujian | Guangdong | Shanghai | Beijing | Jilin |
| No. of Employees | 1,144 | 3,197 | 2,033 | 1,098 | 1,821 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li-Mou Zheng | Chairman | Executive Board | 2015 | 72 |
| Ruan Li | Director; Senior Vice President | Executive Board | 2023 | 47 |
| Luo Jiemin | General Manager; Director | Executive Board | 2021 | 42 |
| Frank Ron Zheng | Director; Senior Vice President | Executive Board | 2021 | 35 |
| Yang Shuang | Deputy General Manager | Senior Management | 2025 | 38 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer